logo-loader
viewSareum Holdings PLC

Sareum Holdings PLC heartened by Sierra Oncology progress

Sareum Holdings Plc (LON:SAR) chief executive, Dr Tim Mitchell, talked to Proactive Investors’ Andrew Scott about Sierra Oncology, which is the licence-holder for the Sareum-developed SRA737 cancer drug.

Mitchell said he's heartened Sierra is more than doubling the size of two phase II clinical trials of the treatment (one underway, the other upcoming).

He is also impressed by the methodology used by Sierra’s researchers that is hoped will glean the best results.

“Rather than screen all-comers they [Sierra] are looking to pre-screen patients for mutations that are most likely to respond to CHK-1 [checkpoint kinase 1] inhibitors so the chances of seeing efficacy we hope are very good,” he told Proactive’s Scott.

Quick facts: Sareum Holdings PLC

Price: 0.38 GBX

AIM:SAR
Market: AIM
Market Cap: £11.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls Bears & Brokers: Martin Place Securities Barry Dawes on a new uptick...

Martin Place Securities executive chairman Barry Dawes speaks to Proactive about gold jumping nicely to pass through US$1600 an ounce, and silver also moving upwards through US$18. Dawes talks about the markets and why the US dollar is strong while the euro is weak. He also covers this...

4 hours, 43 minutes ago

2 min read